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Abstract
Background  and  objective:  Postoperative  pain  treatment  in  mastectomy  remains  a  major  chal-
lenge despite  the  multimodal  approach.  The  aim  of  this  study  was  to  investigate  the  analgesic
effect of  intravenous  lidocaine  in  patients  undergoing  mastectomy,  as  well  as  the  postoperative
consumption  of  opioids.
Methods:  After  approval  by  the  Human  Research  Ethics  Committee  of  the  Instituto  de  Medicina
Integral Prof.  Fernando  Figueira  in  Recife,  Pernambuco,  a  randomized,  blind,  controlled  trial
was conducted  with  intravenous  lidocaine  at  a  dose  of  3  mg/kg  infused  over  1  h  in  45  women
undergoing  mastectomy  under  general  anesthesia.  One  patient  from  placebo  group  was.
Results:  Groups  were  similar  in  age,  body  mass  index,  type  of  surgery,  and  postoperative  need
for opioids.  Two  of  22  patients  in  lidocaine  group  and  three  of  22  patients  in  placebo  group
requested  opioid  (p  =  0.50).  Pain  on  awakening  was  identiﬁed  in  4/22  of  lidocaine  group  and  5/22
of placebo  group  (p  =  0.50);  in  the  post-anesthetic  recovery  room  in  14/22  and  12/22  (p  =  0.37)
of lidocaine  and  placebo  groups,  respectively.  Pain  evaluation  24  h  after  surgery  showed  that
2/22 and  3/22  patients  (p  =  0.50)  of  lidocaine  and  placebo  groups,  respectively,  complained  of
pain.
Conclusion:  Intravenous  lidocaine  at  a  dose  of  3  mg/kg  administered  over  a  period  of  an  hour
during mastectomy  did  not  promote  additional  analgesia  compared  to  placebo  in  the  ﬁrst  24  h,
and has  not  decreased  opioid  consumption.  However,  a  beneﬁcial  effect  of  intravenous  lidocaine
in selected  and/or  other  therapeutic  regimens  patients  cannot  be  ruled  out.a  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.  All  rights© 2014  Sociedade  Brasileir
reserved.∗ Corresponding author.
E-mails: taniacouceiro@yahoo.com.br, taniacursinomcouceiro@gmail.com (T.C.d.M. Couceiro).
http://dx.doi.org/10.1016/j.bjane.2014.05.017
0104-0014/© 2014 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. All rights reserved.
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PALAVRAS-CHAVE
Dor  pós-operatória;
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Anestésico  local;
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Lidocaína  intravenosa  no  tratamento  da  dor  pós-mastectomia:  ensaio  clínico
aleatório  encoberto  placebo  controlado
Resumo
Justiﬁcativa  e  objetivo:  O  tratamento  da  dor  pós-operatória  em  mastectomia  continua  sendo
um grande  desaﬁo  apesar  da  abordagem  multimodal.  O  objetivo  deste  estudo  foi  investigar
o efeito  analgésico  da  lidocaína  intravenosa  em  pacientes  submetidas  a  mastectomia,  como
também, o  consumo  de  opioide  pós-operatório.
Métodos:  Após  aprovac¸ão  pelo  comitê  de  ética  e  pesquisa  em  seres  humanos  do  Instituto  de
Medicina Integral  Prof.  Fernando  Figueira  em  Recife  -  Pernambuco  foi  realizado  ensaio  clínico
aleatório encoberto  placebo  controlado  com  lidocaína  intravenosa  na  dose  de  3  mg/kg  infundida
em uma  hora,  em  45  mulheres  submetidas  a  mastectomia  sob  anestesia  geral.  Excluída  uma
paciente do  grupo  placebo.
Resultados:  Os  grupos  foram  semelhantes  quanto  à  idade,  índice  de  massa  corpórea,  tipo  de
intervenc¸ão cirúrgica  e  necessidade  de  opioide  no  pós-operatório.  Solicitaram  opioide  2/22
pacientes nos  grupos  da  lidocaína  e  3/22  placebo  (p  =  0,50).  Identiﬁcada  a  dor  ao  desper-
tar em  4/22  no  grupo  lidocaína  e  5/22  (p  =  0,50)  no  grupo  placebo;  na  sala  de  recuperac¸ão
pós-anestésica  em  14/22  e  12/22  (p  =  0,37)  nos  grupos  lidocaína  e  placebo  respectivamente.
Ao avaliar  a  dor  24  horas  após  o  procedimento  cirúrgico  3/22  e  2/22  (p  =  0,50)  das  pacientes
relataram  dor  em  ambos  os  grupos  respectivamente.
Conclusão:  A  lidocaína  intravenosa  na  dose  de  3mg/kg  administrada  em  um  período  de  uma
hora no  transoperatório  de  mastectomia  não  promoveu  analgesia  adicional  em  relac¸ão  ao  grupo
placebo nas  primeiras  24  horas  e  não  diminuiu  o  consumo  de  opioide.  Contudo,  um  efeito  bené-
ﬁco da  lidocaína  intravenosa  em  pacientes  selecionadas  e/ou  em  outros  regimes  terapêuticos
não pode  ser  descartado.
© 2014  Sociedade  Brasileira  de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os
direitos reservados.
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ostoperative  pain  remains  inadequately  treated  despite
ts  predictability  and  progress  of  various  analgesic  tech-
iques  and  drugs  available  for  its  control.1 Some  authors
eport  that,  regardless  of  the  type  of  surgical  procedure,
ostoperative  pain  is  present  and  with  varying  intensity.2--4
he  incidence  of  postoperative  pain  in  breast  cancer  is  low
hen  treated  properly,5 however,  it  can  result  in  cardiovas-
ular  and  respiratory  complications,  as  well  as  persistent
ostoperative  pain.6 Therefore,  adequate  pain  control  is  of
aramount  importance  in  clinical  practice.
In  this  context,  the  multimodal  approach  to  postopera-
ive  pain  should  be  considered,  given  the  analgesic  results
btained  with  each  particular  drug  and  the  lower  incidence
f  adverse  effects.6,7
In  order  to  provide  postoperative  analgesia,  intravenous
idocaine  has  been  used  intra-  and  post-operatively  as
art  of  multimodal  approach,8 with  proven  analgesic  effect
n  postoperative  abdominal9 and  pelvic  surgery,  such  as
olectomy10 and  prostatectomy,11 respectively.
In  addition  to  the  analgesic  action,  local  anesthetics  have
nti-inﬂammatory  action,11 justifying  the  use  of  intravenous
idocaine  to  modulate  the  inﬂammatory  response  resulting
12rom  postoperative  pain. Other  beneﬁts  are  the  reduced
eed  for  postoperative  opioids,8,10 reduced  complications
uch  as  nausea  and  vomiting,  and  reduced  pain  intensity  in
he  ﬁrst  24  h.10
t
t
w
dMeta-analyses9,13 show  conﬂicting  results  regarding  the
nalgesic  effect  of  lidocaine  on  postoperative  pain,  high-
ighting  the  need  to  specify  the  real  value  of  intravenous
idocaine  for  postoperative  pain  relief  in  patients  undergoing
astectomy.  The  objective  of  this  study  was  to  investigate
he  analgesic  effect  of  intravenous  lidocaine  in  the  ﬁrst  24  h
n  women  undergoing  mastectomy,  as  well  as  to  assess  the
onsumption  of  opioids  postoperatively.
ethods
fter  approval  by  the  Human  Research  Ethics  Commit-
ee  of  the  Integrative  Medicine  Institute  Prof.  Fernando
igueira  (IMIP),  under  number  2026  CAAE  0202009917210,
nd  obtaining  written  informed  consent  from  participants,  a
andomized,  placebo  controlled,  blind  clinical  trial  was  per-
ormed  from  July  2011  to  August  2012,  at  the  IMIP,  Recife,
ernambuco,  Brazil.
The  study  included  women  aged  between  18  and  75  years
ho  underwent  mastectomy  for  breast  cancer  treatment.
xclusion  criteria  were  patients  with  relative  or  absolute
ontraindication  to  the  use  of  lidocaine  (allergy  to  local
nesthetics,  changes  in  atrioventricular  conduction,  uncon-
rolled  epilepsy,  porphyria,  and  malignant  hyperthermia),
hose  receiving  antidepressants  and/or  anticonvulsants,
ith  cardiac  arrhythmia  and  any  type  of  rheumatic  disease,
istant  metastasis  or  in  contralateral  breast,  patients  who
209
Selection of patients
45 patients interviewed
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Follow-up
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do  not  understand  the  numerical  scale  (NS)  of  pain  assess-
ment  and/or  have  used  opioids  in  the  past  24  h.
Data  were  collected  using  a  standardized  questionnaire
to  characterize  the  sample.  Data  included  age,  body  mass
index  (BMI),  type  of  surgery,  adjuvant  treatment,  and
pain  history,  such  as  headache  and  surgery  breast  pain.
The  variables  studied  were  presence  and  intensity  of  pain
24  h  after  surgery  at  three  different  time  points  (M1  upon
awakening  from  anesthesia,  M2  =  1  h  after  admission  to  the
post-anesthesia  care  unit  (PACU),  and  M3  =  24  h  after  the
surgical  procedure)  and  the  need  for  postoperative  opioids.
Pain  was  assessed  at  rest,  using  a  NS  pain  from  0  to  10  (0  =  no
pain  and  10  =  worst  possible  pain).  For  analysis,  pain  severity
was  categorized  as  absent  (0),  mild  (1--3),  moderate  (4--7),
severe  (7--9),  and  very  severe  (10).
Patients  were  randomly  allocated  into  two  groups  (lido-
caine  or  placebo)  on  a  1:1  ratio  by  drawing  blocks  of  four
patients,  as  in  the  event  of  suspension  or  discontinuation
of  study,  the  number  of  patients  would  remain  similar  in
both  groups.  To  ensure  that  the  study  was  blind,  the  lido-
caine  and  placebo  ampoules  were  prepared  in  similar  vials
and  numbered  sequentially.  All  patients  underwent  general
anesthesia  with  fentanyl  (5  g  kg−1),  propofol  (1.0  mg  kg−1),
and  rocuronium  (0.3  mg  kg−1)  and  maintained  with  1.5%
sevoﬂurane  in  50%  fraction  of  inspired  oxygen.  Bolus  dose
of  lidocaine  was  not  administered  and,  after  incision,  the
1  h  infusion  of  saline  solution  (100  mL)  containing  the  total
dose  of  lidocaine  (3  mg  kg−1)  or  placebo  was  started.
All  patients  received  intravenous  dipyrone  (2  g)  and
ketoprofen  (100  mg)  during  surgery  as  prophylaxis  of  postop-
erative  pain.  The  chest  wall  was  inﬁltrated  with  a  solution
containing  0.025%  bupivacaine  and  epinephrine  1:400,000,
according  to  the  Mastology  Service  conduct.  For  postoper-
ative  analgesia  1  g  dipyrone  was  prescribed  every  6  h.  In
case  of  pain,  codeine  (30  mg)  associated  with  paracetamol
(200  mg)  was  prescribed  to  be  administered  according  to
patients’  request.
The  sample  size  calculation  was  based  on  the  assump-
tion  of  a  5%  alpha-error,  10%  beta-error,  and  90%  power  and
considering  that  lidocaine  group  had  a  70%  reduction  in  opi-
oid  consumption,  while  the  placebo  group  would  have  a  30%
reduction.13 A  loss  of  10%  was  presumed,  resulting  in  44
subjects  divided  into  two  groups  of  22  patients  each.
For  data  analysis,  EPI-INFOTM software  version  3.5.1  for
WindowsTM was  used.  Data  were  presented  as  absolute  and
relative  frequency  distribution  and  presented  in  tables.
Numerical  variables  were  represented  as  measures  of  cen-
tral  tendency  (mean)  and  dispersion  (standard  deviation
and  range).  Chi-square  test  with  Yates’  correction  appli-
cation  and  Fisher’s  exact  test  were  used  to  verify  the
existence  of  an  association  between  categorical  variables.
A  p-value  <  0.05  was  considered  signiﬁcant.
Results
Forty-four  patients  who  underwent  mastectomy  were  eval-
uated,  22  from  lidocaine  group  and  22  from  placebo  group
(Fig.  1,  ﬂowchart).  One  patient  from  placebo  group  was
excluded  because,  although  she  has  shown  to  understand
how  to  use  the  proposed  rating  scale  of  pain  (NS)  and  there-
fore  have  been  included  in  the  study,  she  could  not  evaluate
i
o
rFigure  1  CONSORT  ﬂowchart.  n,  number  of  patients.
he  pain  using  the  NS  postoperatively.  The  groups  were
imilar  in  age,  body  mass  index,  adjuvant  chemotherapy
reatment  before  mastectomy,  and  history  of  pain  (Table  1).
egarding  the  type  of  surgery,  two-thirds  of  patients  in
oth  groups  underwent  Madden’s  mastectomy  and  the  other
ne-third  underwent  mastectomy  with  sentinel  lymph  node
emoval  (Table  1).
There  was  no  difference  between  groups  regarding  post-
perative  pain  at  rest  in  any  of  the  time  points  assessed:
pon  awakening  from  anesthesia  (M1),  1  h  after  PACU  admis-
ion  (M2),  and  24  h  after  the  surgical  procedure  (M3)
Table  2).
Opioid  consumption  in  the  ﬁrst  24  h  after  surgery  was
imilar  in  the  lidocaine  and  placebo  groups  (Table  2).
iscussion
his  study  demonstrated  that  intravenous  administration  of
idocaine  during  surgery  at  a  dose  of  3  mg  kg−1 in  1  h  was  not
uperior  to  placebo  for  postoperative  analgesia  in  patients
ndergoing  mastectomy.
Other  authors10 reported  beneﬁt  with  the  use  of  intra-
enous  lidocaine  for  postoperative  pain  relief.  The  authors
ound  improved  analgesia  in  patients  undergoing  laparo-
copic  colectomy  when  using  an  initial  dose  of  1.5  mg  kg−1
ollowed  by  continuous  infusion  of  2.0  mg  kg−1 g,  which
asted  for  24  h  postoperatively.
De  Oliveira  et  al.14 evaluating  pain  in  women  undergo-
ng,  ambulatory  laparoscopic  surgery  who  received  lidocaine
1.5  mg  kg−1)  20  min  prior  to  surgical  incision,  followed  by  an
−1 −1nfusion  of  2  mg  kg h up  to  the  end  of  surgical  procedure,
bserve  pain  relief  in  the  lidocaine  group.
The  lidocaine  beneﬁt  evidenced  by  these  authors  may  be
elated  to  the  different  infusion  regimens  used.  The  infusion
210  T.C.d.M.  Couceiro  et  al.
Table  1  Sample  characterization  according  to  groups.
Characteristic  Lidocaine  Placebo  p
Age  (years)a 52.4  ±  12.4  47.0  ±  11.0  0.10b
BMIa 28.1  ±  8.1  28.2  ±  3.9  0.89b
Prior  QT  11/22  (50%)  10/22  (45.4%)  0.38c
Headache  6/22  (30%)  9/22  (40.9%)  0.34c
Breast  pain  10/22  (45.5%)  8/22  (36.3%)  0.37c
Madden’s  mastectomy  17/22  (77.2%)  17/22  (77.2%)  --
QT, chemotherapy; BMI, body mass index.
a Mean ± standard deviation.
b Chi-square test.
c Yates’ correction and Fisher’s exact test.
Table  2  Occurrence  and  intensity  of  pain  at  three  different  times  and  postoperative  opioid  requirement  in  24  h.
Lidocaine  Placebo  p
n  %  n  %
Postoperative  pain
Upon  awakening  4/22  18.1  5/22  22.7  0.50
1st hour  of  PO  (PACU)  14/22  63.6  12/22  63.4  0.37
24th hour  of  PO  11/22  50.0  12/22  54.5  0.50
Pain in  a  24-h  period
Mild  to  moderate  20/22  90.9  19/22  86.3  0.50
Severe to  very  severe  24  h  2/22  9.09  3/22  13.6
Postoperative  opioid  use
Opioid  24  h 3/22  13.6  2/22  9.0  0.50
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dn, sample; Opioid 24 h, opioid requirement in the ﬁrst 24 h after s
f  lidocaine  for  24  h  postoperatively  may  have  resulted  in
uppression  of  central  sensitization15 and  thus  contributed
o  obtain  good  analgesic  effect  in  comparison  with  our  study.
he  use  of  bolus  before  surgery  may  lead  us  to  think  that
he  administration  of  lidocaine  before  surgical  incision  can
romote  better  postoperative  pain  results  by  reducing  the
elease  of  inﬂammatory  substances.
Regarding  the  dose,  in  a  recent  study16 using  intra-
enous  lidocaine  in  patients  who  underwent  mastectomy,
he  authors  evaluated  36  patients  divided  into  two  groups,
ith  19  women  in  the  placebo  group  and  17  in  the  lidocaine
roup.  Lidocaine  was  administered  at  a  dose  of  1.5  mg  kg−1
efore  surgical  incision,  followed  by  the  same  dose  every
our,  which  lasted  up  to  60  min  after  closing  the  surgical
ncision.  The  perioperative  conduct  for  postoperative  pain
anagement  was  the  use  of  ketorolac  at  a  single  dose  of
0  mg.  The  authors  found  that  lidocaine  was  able  to  pro-
ide  superior  analgesia  to  placebo  only  in  the  fourth  hour
fter  surgery.  These  authors16 found  a  decrease  in  the  cen-
ral  hyperalgesia  and  a  decreased  incidence  and  severity  of
ersistent  postoperative  pain  in  the  lidocaine  group.
In  our  study,  the  absence  of  additional  analgesic  effect
n  the  early  postoperative  period  (ﬁrst  4  h  after  surgery)
n  the  lidocaine  group  may  have  been  masked  by  the  efﬁ-
iency  of  the  preconized  postoperative  pain  prophylaxis,  as
e  the  administration  of  ketoprofen  (100  mg)  and  dipyrone
2  g)  followed  by  dipyrone  (1  g)  every  6  h  for  24  h  was  system-
tized.  Associated  with  these  drugs,  inﬁltration  of  the  chest
u
i
try; PACU, post-anesthesia care unit; PO, postoperative.
all  ipsilateral  to  the  mastectomy  with  local  anesthetic  and
asoconstrictor  was  performed  in  all  patients.
Currently,  there  is  no  consensus  about  the  best  lidocaine
dministration  method.  Several  infusion  regimens  have  been
sed:  exclusively  during  surgery,8 intraoperatively  and  con-
inued  for  1  h16 or  24  h10,  and  even  as  patient-controlled
nalgesia.17 However,  in  our  study  the  choice  of  lidocaine
dministration  for  a period  of  1  h without  using  an  initial
ose  (bolus)  was  based  on  a  report  of  another  study  by  this
nvestigator,18 which  showed  beneﬁt  when  using  intravenous
idocaine  for  a  short  period  of  time,  and  because  the  surgical
rocedure  in  the  institution  usually  has  an  average  duration
f  1  h.
The  choice  of  the  3  mg  kg−1 dose  was  based  on  the  anal-
esics  results  of  therapeutic  doses  used  in  clinical  practice
2--5  mg  mL−1),  which  achieved  serum  levels  of  2  g mL−1.
ecause  the  mild  adverse  effects  begin  with  serum  levels
bove  3  g  mL−1, this  dose  results  in  a  safety  pharmacology
indow  for  the  use  of  intravenous  lidocaine.19,20
Therefore,  studies  that  stipulate  the  beginning  of  IL  infu-
ion  in  relation  to  the  surgical  incision  time,  duration  of
nfusion  in  the  postoperative  period,  and  the  total  dose  of
ntravenous  lidocaine  to  be  administered  are  required  to
eﬁne  its  actual  role  in  postoperative  analgesia  in  women
ndergoing  mastectomy.
However,  the  non-observation  of  analgesic  advantages
n  patients  undergoing  mastectomy  may  be  more  related
o  the  type  of  pain  resulting  from  surgical  procedure  than
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properly  to  the  infusion  regimen  used,  as  the  pain  resulting
from  cholecystectomies  has  visceral  origin,  while  the  post-
mastectomy  pain  has  somatic  origin.  On  the  other  hand,  it
should  be  considered  that  the  severity  of  pain  in  the  postop-
erative  period  of  this  surgery  varies  from  mild  to  moderate
and  the  use  of  simple  analgesics  such  as  dipyrone  associated
with  anti-inﬂammatory  drugs  results  in  adequate  analgesia.
In  this  study,  opioid  requirement  was  equal  in  both
groups.  These  data  are  similar  to  those  reported  by  other
authors  who  evaluated  opioid  consumption  in  women  under-
going  mastectomy.16 This  result  differs  from  studies  with
outpatients  undergoing  laparoscopic  surgery,14 laparoscopic
colectomy,10 and  cholecystectomies,21 in  which  the  authors
observed  a  decrease  of  about  50%  in  opioid  consumption
during  the  ﬁrst  24  h.
A  human  study22 shows  that  there  is  an  excitatory  action
of  the  local  anesthetic  in  the  intestine  smooth  muscle
and  thus  a  decreased  colonic  distension  and  postoperative
discomfort.  This  action  justiﬁes  the  lidocaine  ability  to  alle-
viate  visceral  pain,  as  demonstrated  in  animal  models23,24
and  proven  from  the  reported  results  in  abdominal  surgery.
This  positive  analgesic  response  in  abdominal  surgery  can
probably  be  explained  by  the  inhibitory  action  of  intravenous
lidocaine  in  visceromotor  reﬂexes  secondary  to  colon  and
rectum  distention,  which  contributes  to  the  relief  of  vis-
ceral  pain.9,10,13 It  is  noteworthy  that  in  the  pain  caused  by
hip  arthroplasty25 and  mastectomy,16 intravenous  lidocaine
did  not  promote  analgesia,  probably  because  these  surgical
procedures  result  in  somatic  pain  that  is  less  inhibited  by
lidocaine.26
This  ﬁnding  helps  to  emphasize  the  hypothesis  that
intravenous  lidocaine  has  a  preferred  analgesic  effect  on
visceral9,10,13 and  neuropathic26,27 pain.  However,  recent
studies  have  demonstrated  that  intravenous  lidocaine  has
analgesic13 and  antihyperalgesic28,29 actions  resulting  from
peripheral  blockade  of  ectopic  impulses  involved  in  nocicep-
tion  and  also  from  its  action  on  potassium  channels,  calcium
channels,  and  G-protein  coupled  receptors.  It  also  has  anti-
inﬂammatory  action 30,31,  an  effect  resulting  from  the  lower
neutrophil  accumulation  at  the  site  of  injury  and  reduced
release  of  inﬂammatory  mediators.29,30 These  actions  justify
its  use  in  multimodal  approach  to  postoperative  analgesia.
Some  limitations  of  this  study  should  be  considered.  Pain
was  assessed  only  at  rest.  It  is  known  that  pain  can  arise  or
worsen  with  limb  movement  on  the  operated  side,  and  pain
assessment  at  this  point  could  bring  additional  information.
Pain  on  movement  was  not  assessed  because  not  moving
the  operated  side  member  in  the  ﬁrst  24  h  after  the  sur-
gical  procedure  is  the  Mastology  Service  protocol.  The  pain
symptom  evaluation  was  performed  for  a  short  period  after
surgery  (24  h).  However,  Grigora  et  al.16 found  no  difference
between  pain  scores  when  evaluated  patients  undergoing
mastectomy  up  to  the  seventh  postoperative  day.
Regarding  persistent  postoperative  pain  after  mastec-
tomy,  the  beneﬁt  of  lidocaine  has  been  observed.16 However,
this  type  of  pain  was  not  assessed  in  our  study.
Therefore,  additional  studies  are  needed  to  identify  the
lowest  dose  able  to  promote  analgesia,  ‘‘What  is  the  most
appropriate  regime  for  infusion?’’,  and  ﬁnally,  identify  the
value  of  lidocaine  in  the  multimodal  treatment  of  acute
and  chronic  postoperative  pain.  Thus,  in  this  study,  intra-
venous  lidocaine  at  a  dose  of  3  mg  kg−1 administered  over  a
1211
 h  period  perioperatively  during  mastectomy  did  not  pro-
ote  additional  analgesia  compared  to  placebo  within  the
rst  24  h  and  did  not  decrease  opioid  consumption.  How-
ver,  a  beneﬁcial  effect  of  intravenous  lidocaine  in  selected
atients  and/or  other  therapeutic  regimens  cannot  be  ruled
ut.
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